Patent · US Expired

Production of adenovirus vectors with reduced levels of replication competent adenovirus contamination

US7189561B2 · kind B2 · utility

1Cited by
3References
12Claims
0Family size

Assignee

Inventor

Key dates

Filing dateSep 21, 2004
Grant dateMar 13, 2007
Priority date
Expiry dateJan 20, 2025

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2840/20
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Methods, cells and recombinant adenoviral vectors are disclosed that permit the production of recombinant adenoviral vector stocks with reduced levels of contamination by replication competent adenoviruses (RCA). In certain embodiments are disclosed early region 1 (E1) deficient recombinant adenoviral vectors and complementing E1 positive host cells whose sequences are designed to avoid formation of RCA by homologous recombination between sequences in the vector and E1 sequences in the cells. One aspect of the invention involves the inversion of the packaging signal in a recombinant adenoviral vector relative to an adjacent or nearby inverted terminal repeat (ITR). Methods include use of site-specific intregrase family recombinases such as Cre or FLP and recombinase recognition sites such as lox sites or frt sites.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.